Our results confirmed the synergistic effect of ATR/Chk1 inhibitors and gemcitabine in OTUD6A-overexpressing BCa cells, suggesting the possible beneficial effects of targeting ATR/Chk1 in cancers with high expression of OTUD6A and CDC6. Here, ATR is linked to cancer.